Xenon Pharmaceuticals (XENE) Q1 2025 earnings summary

Executive summary

• Patient recruitment for the pivotal XTOL-2/X-TOLE2 phase 3 epilepsy study is nearing completion, with top-line results expected early 2026, slightly delayed from prior guidance.

• Azetukalner, a Kv7 channel opener, continues to show promise in epilepsy and neuropsychiatric disorders, with over 700 patient-years of exposure and sustained efficacy and safety data.

• Expanding clinical development into major depressive disorder (MDD) and bipolar depression (BPD), with multiple phase 3 studies ongoing or set to initiate by mid-year.

• Early-stage pipeline advancing, including first-in-human studies for XEN1120 (Kv7 opener for pain) and XEN1701 (Nav1.7 inhibitor for pain), and preclinical progress in Nav1.1 for Dravet syndrome.

• Net loss of $65.0 million for Q1 2025, up from $47.9 million year-over-year, driven by increased R&D and G&A expenses.

Financial highlights

• Recognized $7.5 million in Q1 2025 revenue from a milestone payment related to a Neurocrine collaboration.

• Cash, cash equivalents, and marketable securities totaled $691.1 million as of March 31, 2025, down from $754.4 million at year-end 2024.

• Research and development expenses were $61.2 million, up $17.0 million year-over-year, mainly due to phase 3 trials and increased headcount.

• General and administrative expenses increased to $19.0 million, primarily from higher personnel costs.

• Sufficient cash runway to fund operations into 2027, supporting late-stage and early-stage pipeline development.

Outlook and guidance

• Top-line results from XTOL-2/X-TOLE2 phase 3 epilepsy study expected early 2026, with NDA filing anticipated approximately six months after data readout if positive.

• Two phase 3 MDD studies (XNOVA-2 and XNOVA-3) and a phase 3 BPD study expected to be underway by mid-year.

• Continued expansion of early-stage pipeline with multiple IND/CTA filings and first-in-human studies planned for 2025.

• Anticipates continued increase in operating expenses as late-stage clinical programs progress and commercialization preparations advance.